Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

C2210000

Cisplatin

European Pharmacopoeia (EP) Reference Standard

Sinonimo/i:

cis-Diammineplatinum(II) dichloride, cis-Dichlorodiammine platinum(II), cis-Platinum(II) diammine dichloride, Cisplatin

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula condensata:
Pt(NH3)2Cl2
Numero CAS:
Peso molecolare:
300.05
Numero CE:
Numero MDL:
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

pharmaceutical primary standard

Famiglia di API

cisplatin

Produttore/marchio commerciale

EDQM

Punto di fusione

270 °C (lit.)

applicazioni

pharmaceutical (small molecule)

Formato

neat

Stringa SMILE

N.N.Cl[Pt]Cl

InChI

1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2
LXZZYRPGZAFOLE-UHFFFAOYSA-L

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets, has been developed and issued under the Authority of the Issuing Pharmacopoeia.

For further information and support please go to the website of the issuing Pharmacopoeia.

Applicazioni

This European Pharmacopoeia reference standard is intended for use only as specifically prescribed in the European Pharmacopoeia. Their suitability for any other use is not guaranteed and is the sole responsibility of the user. This standard is not intended for human or animal use.
Established for the preparation of the below-given solutions as per European Pharmacopoeia:
  • Reference solutions in the identification using infrared absorption spectroscopy and thin-layer chromatography, testing of related substances, and assay using liquid chromatography (General text 2.2.29) of cisplatin, according to the monograph 0599
  • Reference solution (b) for the testing of related substances in carboplatin using liquid chromatography (General text 2.2.29), according to the monograph 1081

Azioni biochim/fisiol

Potent platinum-based antineoplastic agent. Forms cytotoxic adducts with the DNA dinucleotide d(pGpG), inducing intrastrand cross-links.

Confezionamento

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Altre note

Sales restrictions may apply.

Pittogrammi

Skull and crossbonesHealth hazard

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 2 Oral - Carc. 1B - Eye Irrit. 2 - Resp. Sens. 1 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

Organi bersaglio

Respiratory system

Codice della classe di stoccaggio

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 9

1 of 9

Doxorubicina European Pharmacopoeia (EP) Reference Standard

D2975000

Doxorubicina

Oxaliplatin powder

Sigma-Aldrich

O9512

Oxaliplatin

Carboplatin British Pharmacopoeia (BP) Reference Standard

BP711

Carboplatin

Oxaliplatin European Pharmacopoeia (EP) Reference Standard

Y0000271

Oxaliplatin

5-Fluorouracil ≥99% (HPLC), powder

Sigma-Aldrich

F6627

5-Fluorouracil

Doxorubicina 98.0-102.0% (HPLC)

Sigma-Aldrich

D1515

Doxorubicina

Paclitaxel European Pharmacopoeia (EP) Reference Standard

Y0000698

Paclitaxel

Etoposide European Pharmacopoeia (EP) Reference Standard

E2600000

Etoposide

Cisplatin
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 2231-2232 (2009)
Michael F Milosevic et al.
International journal of cancer, 135(7), 1692-1699 (2013-08-02)
Radiotherapy (RT) with concurrent cisplatin (CRT) is standard treatment for locally advanced cervical cancer. However, not all patients benefit from the addition of cisplatin to RT alone. This study explored the value of pretreatment tumor interstitial fluid pressure (IFP) and
Yi-Long Wu et al.
The Lancet. Oncology, 14(8), 777-786 (2013-06-21)
The results of FASTACT, a randomised, placebo-controlled, phase 2 study, showed that intercalated chemotherapy and erlotinib significantly prolonged progression-free survival (PFS) in patients with advanced non-small-cell lung cancer. We undertook FASTACT-2, a phase 3 study in a similar patient population.
James Chih-Hsin Yang et al.
The Lancet. Oncology, 16(2), 141-151 (2015-01-16)
We aimed to assess the effect of afatinib on overall survival of patients with EGFR mutation-positive lung adenocarcinoma through an analysis of data from two open-label, randomised, phase 3 trials. Previously untreated patients with EGFR mutation-positive stage IIIB or IV
Vicente Fresquet et al.
Blood, 123(26), 4111-4119 (2014-05-03)
Acquired resistance to targeted drugs is emerging as an obstacle to successful cancer treatment. Recently, a BCL2-selective BH3 mimetic termed ABT-199 showed promising therapeutic results in BCL2-dependent tumors. Based on its high affinity for BCL2, we studied potential mechanisms conferring

Articoli

Antineoplastic agents separated with excellent resolution.

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.